Mr. Gero became Chairman of Orthofix International N.V. on Jan. 1, 2005, and has been a Director of Orthofix International N.V. since 1998. Mr. Gero became a Director of AME Inc. in 1990. He is a Director of Intrusion, Inc. and Drew Industries Inc. as well as being a private investor.

Holdings: 122,504 shares     View Transactions
Date	Type	Shares Traded	Price Range
Nov 11, 2008	Buy	20,000	12.99
May 8, 2008	Buy	4,500	37.90
May 7, 2008	Buy	3,000	37.24
May 6, 2008	Buy	7,500	36.17
May 11, 2007	Buy	10,000	47.28 - 47.35
Aug 25, 2006	Buy	8,676	39.50 - 39.69
Aug 18, 2006	Buy	15,224	38.78
Aug 17, 2006	Buy	1,100	38.81

Mr. Milinazzo joined Orthofix International in 2005 as Chief Operating Officer and succeeded to the position of CEO the following year. Prior to joining Orthofix, Mr. Milinazzo was Vice President of Medtronic Inc.'s Vascular business, as well as, Vice President and General Manager of Medtronic's Coronary and Peripheral businesses. Prior to his time with Medtronic, Mr. Milinazzo spent 12 years as an executive with Boston Scientific Corporation in numerous roles, including Vice President of Marketing for SCIMED Europe. Mr. Milinazzo brings more than two and a half decades of experience in the management and marketing of medical device businesses, including positions with Aspect Medical Systems and American Hospital Supply. He earned a bachelor's degree, cum laude, at Boston College in 1981.

Dr. von Wartburg became a non-executive Director of Orthofix International N.V. in June 2004. He is an attorney and has practiced privately in his own law firm in Basel, Switzerland since 1999, specializing in life sciences law. He has also been a professor of administrative law and public health policy at the Saint Gall Graduate School of Economics in Switzerland for 25 years. Previously, he held top management positions with Ciba Pharmaceuticals and Novartis at their headquarters in Basel, Switzerland. In addition, Mr. von Wartburg currently serves as a Director on the board of Nymox Pharmaceutical Corporation.

Dr. Jordan became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Dr. Jordan served as a group president at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard's global oncology business and functional responsibility for all of Bard's research and development. Dr. Jordan earned a Ph.D. in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. He also currently serves on the boards of Specialized Health Products International, Inc., Xillix Technologies Corporation and EsophyX, Inc.

Ms. Sainz was elected to the Orthofix International Board of Directors in 2008. She currently serves as the President and CEO of Concentric Medical. Prior to joining Concentric Medical she was President of Guidant Corporation's Cardiac Surgery Division and a member of Guidant's Management Committee prior to their acquisition by Boston Scientific. She gained significant experience in the medical device market with Lilly MDD, Guidant and Boston Scientific. Ms. Sainz holds a Bachelors and Masters Degree of Arts from the Universidad Complutense de Madrid, and a Masters Degree in International Management from AGSIM in Arizona.